Open an account

Travere Therapeutics

TVTX · NASDAQ

$52.30+$1.81 (+3.58%)TodayMarket closed ·
Prev close $50.49

About TVTX

Travere Therapeutics, Inc. is a biopharmaceutical company. The company is headquartered in San Diego, California and currently employs 497 full-time employees. The company went IPO on 2003-07-23. The firm is focused on identifying, developing, and delivering life-changing therapies to people living with rare kidney and metabolic diseases. Its product, FILSPARI (sparsentan), is indicated to reduce proteinuria in adults with primary IgAN at risk of rapid disease progression. FILSPARI is an oral, once-daily, non-immunosuppressive medication that directly targets glomerular injury in the kidney. Sparsentan is also in late-stage development for focal segmental glomerulosclerosis (FSGS). The Company’s Pegtibatinase is a novel investigational human enzyme replacement candidate being evaluated for the treatment of classical homocystinuria (HCU), which is a rare metabolic disorder. Its commercial products, Thiola and Thiola EC, are for the treatment of cystinuria, a rare genetic cystine transport disorder that causes high cystine levels in the urine and the formation of recurring kidney stones.

Employees
497
Headquarters
San Diego, California
Listed
Jul 23, 2003
Sector
Health Care
Industry
Biotechnology
Website
travere.com

TVTX key statistics

Market cap
4.93B
Price-earnings ratio
0.00
Dividend yield
—
Average volume
1.94M
Volume
2.06M
Open price
$50.43
High today
$52.70
Low today
$50.40
52 Week high
$68.73
52 Week low
$22.59

Travere Therapeutics (TVTX) at a glance

As of Oct 20, 2026, Travere Therapeutics (TVTX) shares are priced at $52.30, giving the company a market cap of 4.93B and a price-to-earnings ratio of 0.00.

Today the stock has traded between $50.40 and $52.70. The current price is 3.8% above the day's low and 0.8% below its high.

Volume so far is 2.06M shares, in line with the average of 1.94M shares a day.

Over the past year Travere Therapeutics has ranged from $22.59 to $68.73, and now sits 64% of the way up that range.

Travere Therapeutics met or beat analyst EPS estimates in 5 of the last 8 quarters. In Q2 FY26 it reported $0.06 per share against an estimate of -$0.1415.

The average analyst price target is $75.56, 44.5% above the current price, from 10 recent ratings.

Analyst ratings

Latest rating from each analyst over the past 12 months

90%of 10 analyst ratings say Buy
  • Buy90.0%
  • Hold10.0%
  • Sell0.0%
Price target · 16 analystsAvg $75.56
Low
$62.62
Now
$52.30
High
$93.45

TVTX earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 5 of the last 8 quarters, by 113.6% on average.

  1. Q3 FY24: reported -$0.70 per share against an estimate of -$0.6931
  2. Q4 FY24: reported -$0.73 per share against an estimate of -$0.5735
  3. Q1 FY25: reported -$0.47 per share against an estimate of -$0.5508
  4. Q2 FY25: reported -$0.14 per share against an estimate of -$0.3037
  5. Q3 FY25: reported $0.28 per share against an estimate of -$0.212
  6. Q4 FY25: reported $0.03 per share against an estimate of -$0.1204
  7. Q1 FY26: reported -$0.40 per share against an estimate of -$0.2709
  8. Q2 FY26: reported $0.06 per share against an estimate of -$0.1415

TVTX news

  • Erica Kollmann

    FTC Says Martin Shkreli ‘Flagrantly’ Violated Lifetime Pharma Ban With Drug Stock Trades

  • Press releaseBusiness Wire

    Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

  • Press releaseBusiness Wire

    Travere to Present New Data Supporting FILSPARI® (sparsentan) as Foundational Treatment in IgA Nephropathy and FSGS at ASN Kidney Week 2026

  • Press releasePRNewswire

    Kuehn Law Encourages Investors of Travere Therapeutics, Inc. to Contact Law Firm

  • Press releaseBusiness Wire

    Travere Therapeutics Receives Notice of Allowance from the U.S. Patent and Trademark Office for U.S. Patent Application Directed to Certain Methods of Using FILSPARI® (sparsentan) in Focal Segmental Glomerulosclerosis

  • Press releaseBusiness Wire

    Travere Therapeutics Announces Planned Chief Executive Officer Transition

  • Press releaseBusiness Wire

    Travere Therapeutics to Present at the Stifel 2026 Virtual Immunology and Inflammation Forum

  • Press releaseBusiness Wire

    Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Similar companies

Companies in the same industry as Travere Therapeutics

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.